Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

NCT05375084 is registered in ClinicalTrials.gov with Navire Pharma Inc., a BridgeBio company as lead sponsor.

NCT NCT05375084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05375084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Lead sponsor
Navire Pharma Inc., a BridgeBio company
Phase
Phase 1
Overall status
Terminated
Start date
October 20, 2022
Completion date
July 15, 2024
Enrollment
21 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, solid tumor